Core Insights - Fortress Biotech, Inc. has initiated the commercial launch of Emrosi™ for treating inflammatory lesions of rosacea in adults, following FDA approval in November 2024 [4] - The company reported a net loss of $(12.7) million, or $(0.48) per share, for Q1 2025, an improvement from a net loss of $(17.9) million, or $(1.04) per share, in Q1 2024 [12][18] - Fortress' subsidiary Checkpoint Therapeutics is set to be acquired by Sun Pharma, with expected upfront cash payment of approximately $28 million and potential future royalties [3][2] Financial Results - Fortress' consolidated cash and cash equivalents increased to $91.3 million as of March 31, 2025, up from $57.3 million at the end of 2024, marking a $34 million increase [12][14] - Consolidated net product revenue for Q1 2025 was $13.1 million, slightly up from $13.0 million in Q1 2024 [9][18] - Research and development expenses for Q1 2025 totaled $3.9 million, a significant decrease from $24.8 million in Q1 2024 [12][18] Regulatory Updates - The FDA accepted the New Drug Application for CUTX-101 for Menkes disease, with a PDUFA goal date of September 30, 2025 [2][8] - UNLOXCYT, an anti-PD-L1 antibody developed by Checkpoint, was approved by the FDA in December 2024 for treating patients with metastatic or locally advanced cutaneous squamous cell carcinoma [8] Commercial Product Updates - Emrosi was launched by Journey Medical Corporation, with initial prescriptions filled at the end of March 2025 [4][18] - Full results from two Phase 3 clinical trials evaluating Emrosi were published, demonstrating its efficacy and safety for treating moderate-to-severe papulopustular rosacea [18] Corporate Highlights - Fortress has a robust pipeline with multiple late-stage programs and newly approved products, positioning the company for continued revenue growth [2] - The acquisition of Checkpoint by Sun Pharma is expected to enhance patient access to Checkpoint's products and create significant monetization opportunities for Fortress [3][2]

CINCINNATI, May 15, 2025 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that Chairman and Chief Executive Officer Jeff Edison, President Bob Myers and Chief Financial Officer John Caulfield will present at Nareit REITweek on Tuesday, June 3, 2025 at 8:45 a.m. Eastern Time. Presentation Details: Date: Tuesday, June 3, 2025 Time: 8:45 ...

GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the proposed offering, Senseonics also expects to grant the underwr ...

Company reports first quarter 2025 revenue growth of 153% with 28% pro-forma adjusted EBITDA margin Confirms projected 2025 revenue of $30–35 million and 28% EBITDA margin Conference call today at 5:00 pm ET to discuss results DENVER, May 15, 2025 (GLOBE NEWSWIRE) -- Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial services and intelligence solutions, today announced first quarter 2025 results and affirmed 2025 guidance. For the first quarter end ...

Core Insights - Outlook Therapeutics is on track to transition into a commercial-stage company with the planned launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for wet AMD treatment in Q2 2025 [2][3] - The company anticipates potential FDA approval for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in the US by August 27, 2025, which would provide a much-needed approved ophthalmic formulation of bevacizumab [2][6] Financial Performance - For the fiscal second quarter ended March 31, 2025, the company reported a net loss of $46.4 million, or $1.50 per share, a significant reduction from a net loss of $114.3 million, or $8.01 per share, in the same period last year [10][26] - The adjusted net loss for the same period was $12.5 million, or $0.40 per share, compared to an adjusted net loss of $22.1 million, or $1.55 per share, for the fiscal second quarter of 2024 [10][11] Product Development and Regulatory Updates - LYTENAVA™ (bevacizumab gamma) is the first authorized ophthalmic formulation of bevacizumab for wet AMD in the EU and UK, with approximately 2.8 million injections annually in Europe and 2.7 million in the US for retinal diseases [4][16] - The FDA has acknowledged the resubmission of the Biologics License Application (BLA) for ONS-5010, which is undergoing a Class 2 review with a six-month review period [6][9] Market Strategy and Collaborations - Outlook Therapeutics has entered a strategic collaboration with Cencora to support the global commercial launch of LYTENAVA™ following regulatory approvals, aiming for efficient distribution and market access [5][16] - The company is also exploring authorization in additional European countries and Japan, indicating a broader market strategy [5]

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2025 with $398.2 Million in Cash, Cash Equivalents and Marketable Securities; Novo Nordisk Collaborat ...

Multiple Deployments Scheduled throughout 2025 to Showcase AirSCWO Technology Launched Waste Destruction Services and Signed RCRA Part B TSDF Partner Agreement to Expand Onsite Operations New Executive Team and Director Appointments to Drive Commercial Trajectory DURHAM, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today reported its financial and operation ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells and Allo-Evasion ...

West-coast acquisition expands geographic footprint and scaleTORONTO and NANAIMO, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ, TSX: CIGI) announced today that its Canadian engineering platform Englobe Corporation (“Englobe”) has acquired Herold Engineering Limited (“Herold”), a leading engineering consulting firm in British Columbia. Herold’s leadership team will continue to lead these operations and become shareholders of Englobe under Colliers’ unique partnership model. Terms of th ...

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first ...